Showing 3 posts of 3 posts found.

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019
Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …


Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype

November 23, 2018
Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss

Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …


Spark hands over Luxturna rights outside US to Novartis for $170m

January 25, 2018
Sales and Marketing Luxturna, Novartis, Spark Therapeutics, pharma

Novartis has confirmed a deal worth a potential $170 million with Spark Therapeutics to develop and commercialise its gene therapy …

Latest content